Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population

Current Medical Research and Opinion

Volumn 27, Issue 5, 2011, Pages 961-968

  Kamat, Siddhesh A ^a,c   Bullano, Michael F ^b   Chang, Chun Lan ^a   Gandhi, Sanjay K ^b   Cziraky, Mark J ^a  

^a HEALTHCORE INC   (United States)

^b ASTRAZENECA   (United Kingdom)

^c Research Operations   (United States)

Author keywords

Combination; Drug therapy; Dyslipidemias; Managed care programs; Medication adherence

Indexed keywords

EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; DRUG DOSAGE FORM COMPARISON; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PATIENT COMPLIANCE; PILL; RETROSPECTIVE STUDY; TREATMENT REFUSAL;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DATABASES, FACTUAL; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOVASTATIN; MALE; MIDDLE AGED; NIACIN; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SIMVASTATIN; TIME FACTORS;

EID: 79954552035     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.562494     Document Type: Article

References (35)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. (Pubitemid 38924592)
3. Ford ES, Giles WH, Dietz WH. Prevalence the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9. (Pubitemid 34251969)
4. Lin Y, Mousa SS, Elshourbagy N, et al. Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins and triglycerides as targets for therapy. Vasc Health Risk Manag 2010;6:73-85.
5. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates of year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. (Pubitemid 38579764)
6. Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung and Blood Institutes. Circulation 2006;113:2363-72. (Pubitemid 43947981)
7. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-9. (Pubitemid 351410514)
8. Liberopoulos EN, Florentin M, Mikhailidis DP, et al. Compliance with lipidlowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf 2008;7:717-25.
9. Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 2005;27:1639-46. (Pubitemid 41739501)
10. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40.
11. Dragomir A, Cô té R, White M, et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value Health 2010;13:87-94.
12. Balu S, Simko RJ, Quimbo RM, et al. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin 2009;25:2765-75.
13. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2010;3:CD004371.
14. Bangalore S, Kamalakkannan G, Parker S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713-19. (Pubitemid 47176510)
15. National Quality Forum. National Quality Forum Endorses Measures to Improve Medication Safety and Quality. 2009. Aug 17. Available at: http:// www.qualityforum.org/News-And-Resources/Press-Releases/2009/ National-Quality-Forum-Endorses-Measures-to-Improve-Medication-Safety- and-Quality.aspx [Last accessed 17 October 2010].
16. Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cutpoint for adherence measures using administrative claims data. Curr Med Res Opin 2009;25:2303-10.
17. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 2009;10:2973-85.
18. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence- based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177-86. (Pubitemid 46089734)
19. Shalev V, Chodick G, Silber H, et al. Continuation of statin treatment and allcause mortality: a population-based cohort study. Arch Intern Med 2009; 169:260-8.
20. Sokol M, McGuigan K, Verbrugge R, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30. (Pubitemid 40847288)
21. Goldman DP, Joyce GE, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care 2006;12:21-8. (Pubitemid 43139537)
22. Shroufi A, Powles JW. Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. J Epidemiol Community Health 2010;64:109-13.
23. Albert NM. Improving medication adherence in chronic cardiovascular disease. Crit Care Nurse 2008;28:54-64.
24. Touchette DR, Shapiro NL. Medication compliance, adherence, and persistence: current status of behavioral and educational interventions to improve outcomes. J Manag Care Pharm 2008;14:S2-S10.
25. Gibson TB, Mark TL, Axelsen K, et al. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 2006;12:SP11-19. (Pubitemid 46053391)
26. Schultz JS, O'Donnell JC, McDonough KL, et al. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 2005;11:306-12. (Pubitemid 40646935)
27. Doshi JA, Zhu J, Lee BY, et al. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 2009; 119:390-7.
28. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003;349:2224-32. (Pubitemid 37485139)
29. Bangalore S, Kamalakkannan G, Parker S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713-19. (Pubitemid 47176510)
30. Aslam F, Haque A, Lee V, et al. Patient adherence and preference considerations in managing cardiovascular risk: focus on single pill and amlodipine/ atorvastatin fixed combination. Patient Prefer Adherence 2009;3:61-6.
31. Patel BV, Leslie RS, Thiebaud P, et al. Adherence with single-pill amlodipine/ atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008;4:673-81. (Pubitemid 352037925)
32. LaFleur J, Thompson CJ, Joish VN, et al. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother 2006;40:1274-9. (Pubitemid 44204956)
33. Philips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001;135:825-34. (Pubitemid 33051266)
34. Lindgren P, Borgström F, Sta°lhammar J, et al. Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs. Int J Clin Pract 2007;61:1410-14. (Pubitemid 47052375)
35. Goldberg KC, Melnyk SD, Simel DL. Overcoming inertia: improvement in achieving target low-density lipoprotein cholesterol. Am J Manag Care 2007;13:530-4 (Pubitemid 47404430)